ALNYLAM PHARMACEUTICALS, INC. Income Tax Expense
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Income Tax Expense of $13.31 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. income tax expense (benefit) for the quarter ending 2026-06-30 was $13.31M, a 56.95% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. income tax expense (benefit) for the quarter ending 2025-12-31 was -$25.28M.
- ALNYLAM PHARMACEUTICALS, INC. income tax expense (benefit) for the quarter ending 2025-09-30 was -$12.12M, a 516.75% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. income tax expense (benefit) for the quarter ending 2025-06-30 was $30.92M, a 440.35% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. income tax expense (benefit) for fiscal 2025 was $9.40M.
- ALNYLAM PHARMACEUTICALS, INC. income tax expense (benefit) for fiscal 2024 was -$99.22M, a 1575.36% decline from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. income tax expense (benefit) for fiscal 2023 was $6.72M, a 61.54% increase from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. income tax expense (benefit) for fiscal 2022 was $4.16M, a 512.21% increase from fiscal 2021.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.31M 10-Q · filed 2026-07-30 | $28.97M 10-Q · filed 2026-07-30 | ||
| 2025-12-31 | -$25.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$37.40M derived: sum of 2 quarters · filed 2026-02-12 | -$6.48M derived: sum of 3 quarters · filed 2026-07-30 | $9.40M 10-K · filed 2026-02-12 |
| 2025-09-30 | -$12.12M 10-Q · filed 2025-10-30 | $18.80M derived: sum of 2 quarters · filed 2026-07-30 | $34.69M 10-Q · filed 2025-10-30 | -$75.51M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $30.92M 10-Q · filed 2026-07-30 | $46.80M 10-Q · filed 2026-07-30 | -$63.39M derived: sum of 3 quarters · filed 2026-07-30 | -$60.49M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $15.88M 10-Q · filed 2025-05-01 | -$94.31M derived: sum of 2 quarters · filed 2026-02-12 | -$91.41M derived: sum of 3 quarters · filed 2026-02-12 | -$85.68M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | -$110.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$107.29M derived: sum of 2 quarters · filed 2026-02-12 | -$101.57M derived: sum of 3 quarters · filed 2026-02-12 | -$99.22M 10-K · filed 2026-02-12 |
| 2024-09-30 | $2.91M 10-Q · filed 2025-10-30 | $8.63M derived: sum of 2 quarters · filed 2025-10-30 | $10.98M 10-Q · filed 2025-10-30 | $11.16M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $5.72M 10-Q · filed 2025-07-31 | $8.07M 10-Q · filed 2025-07-31 | $8.25M derived: sum of 3 quarters · filed 2026-02-12 | $11.24M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $2.35M 10-Q · filed 2025-05-01 | $2.53M derived: sum of 2 quarters · filed 2026-02-12 | $5.52M derived: sum of 3 quarters · filed 2026-02-12 | $7.33M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $183.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $3.17M derived: sum of 2 quarters · filed 2026-02-12 | $4.99M derived: sum of 3 quarters · filed 2026-02-12 | $6.72M 10-K · filed 2026-02-12 |
| 2023-09-30 | $2.99M 10-Q · filed 2024-10-31 | $4.80M derived: sum of 2 quarters · filed 2024-10-31 | $6.54M 10-Q · filed 2024-10-31 | $7.01M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $1.81M 10-Q · filed 2024-08-01 | $3.55M 10-Q · filed 2024-08-01 | $4.03M derived: sum of 3 quarters · filed 2025-02-13 | $4.00M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | $1.74M 10-Q · filed 2024-05-02 | $2.21M derived: sum of 2 quarters · filed 2025-02-13 | $2.19M derived: sum of 3 quarters · filed 2025-02-13 | $4.92M derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | $472.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $449.00K derived: sum of 2 quarters · filed 2025-02-13 | $3.18M derived: sum of 3 quarters · filed 2025-02-13 | $4.16M 10-K · filed 2025-02-13 |
| 2022-09-30 | -$23.00K 10-Q · filed 2023-11-02 | $2.71M derived: sum of 2 quarters · filed 2023-11-02 | $3.69M 10-Q · filed 2023-11-02 | $1.85M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $2.73M 10-Q · filed 2023-08-03 | $3.71M 10-Q · filed 2023-08-03 | $1.87M derived: sum of 3 quarters · filed 2024-02-15 | $2.15M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $985.00K 10-Q · filed 2023-05-04 | -$857.00K derived: sum of 2 quarters · filed 2024-02-15 | -$579.00K derived: sum of 3 quarters · filed 2024-02-15 | $649.00K derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$1.56M derived: sum of 2 quarters · filed 2024-02-15 | -$336.00K derived: sum of 3 quarters · filed 2024-02-15 | $680.00K 10-K · filed 2024-02-15 |
| 2021-09-30 | $278.00K 10-Q · filed 2022-10-27 | $1.51M derived: sum of 2 quarters · filed 2022-10-27 | $2.52M 10-Q · filed 2022-10-27 | $2.46M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $1.23M 10-Q · filed 2022-07-28 | $2.24M 10-Q · filed 2022-07-28 | $2.19M derived: sum of 3 quarters · filed 2023-02-23 | $3.02M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $1.02M 10-Q · filed 2022-04-28 | $957.00K derived: sum of 2 quarters · filed 2023-02-23 | $1.80M derived: sum of 3 quarters · filed 2023-02-23 | $3.12M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$59.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $780.00K derived: sum of 2 quarters · filed 2023-02-23 | $2.11M derived: sum of 3 quarters · filed 2023-02-23 | $2.68M 10-K · filed 2023-02-23 |
| 2020-09-30 | $839.00K 10-Q · filed 2021-10-28 | $2.17M derived: sum of 2 quarters · filed 2021-10-28 | $2.74M 10-Q · filed 2021-10-28 | $2.34M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-06-30 | $1.33M 10-Q · filed 2021-08-03 | $1.90M 10-Q · filed 2021-08-03 | $1.50M derived: sum of 3 quarters · filed 2022-02-10 | $1.11M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-03-31 | $575.00K 10-Q · filed 2021-04-29 | $177.00K derived: sum of 2 quarters · filed 2022-02-10 | -$217.00K derived: sum of 3 quarters · filed 2022-02-10 | $743.00K derived: sum of 4 quarters · filed 2022-02-10 |
| 2019-12-31 | -$398.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | -$792.00K derived: sum of 2 quarters · filed 2022-02-10 | $168.00K derived: sum of 3 quarters · filed 2022-02-10 | $863.00K 10-K · filed 2022-02-10 |
| 2019-09-30 | -$394.00K 10-Q · filed 2020-11-05 | $566.00K derived: sum of 2 quarters · filed 2020-11-05 | $1.26M 10-Q · filed 2020-11-05 | $1.62M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | $960.00K 10-Q · filed 2020-08-06 | $1.66M 10-Q · filed 2020-08-06 | $2.02M derived: sum of 3 quarters · filed 2021-02-11 | $2.46M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | $695.00K 10-Q · filed 2020-05-06 | $1.06M derived: sum of 2 quarters · filed 2021-02-11 | $1.50M derived: sum of 3 quarters · filed 2021-02-11 | $1.58M derived: sum of 4 quarters · filed 2021-02-11 |
| 2018-12-31 | $361.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $806.00K derived: sum of 2 quarters · filed 2021-02-11 | $885.00K derived: sum of 3 quarters · filed 2021-02-11 | $823.00K 10-K · filed 2021-02-11 |
| 2018-09-30 | $445.00K 10-Q · filed 2019-10-31 | $524.00K derived: sum of 2 quarters · filed 2019-10-31 | $462.00K 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $79.00K 10-Q · filed 2019-08-06 | $17.00K 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | -$62.00K 10-Q · filed 2019-05-02 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-13 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-02-14 | |||
| 2015-12-31 | $0.00 10-K · filed 2016-02-12 | |||
| 2014-12-31 | -$40.21M 10-K · filed 2016-02-12 | |||
| 2013-12-31 | $3.02M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $751.00K derived: sum of 2 quarters · filed 2016-02-12 | -$2.13M derived: sum of 3 quarters · filed 2016-02-12 | -$2.69M 10-K · filed 2016-02-12 |
| 2013-09-30 | -$2.27M 10-Q · filed 2013-11-07 | -$5.15M derived: sum of 2 quarters · filed 2013-11-07 | -$5.72M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | -$2.88M 10-Q · filed 2013-08-09 | -$3.45M 10-Q · filed 2013-08-09 | ||
| 2013-03-31 | -$562.00K 10-Q · filed 2013-05-07 | |||
| 2012-12-31 | -$10.57M 10-K · filed 2015-02-13 | |||
| 2011-12-31 | $0.00 10-K · filed 2014-02-20 | |||
| 2010-12-31 | $427.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-19 | $725.00K derived: sum of 2 quarters · filed 2013-02-19 | $496.00K derived: sum of 3 quarters · filed 2013-02-19 | $514.00K 10-K · filed 2013-02-19 |
| 2010-09-30 | $298.00K 10-Q · filed 2011-11-03 | $69.00K derived: sum of 2 quarters · filed 2011-11-03 | $87.00K 10-Q · filed 2011-11-03 | -$352.00K derived: sum of 4 quarters · filed 2012-02-13 |
| 2010-06-30 | -$229.00K 10-Q · filed 2011-08-03 | -$211.00K 10-Q · filed 2011-08-03 | -$650.00K derived: sum of 3 quarters · filed 2012-02-13 | -$1.20M derived: sum of 4 quarters · filed 2012-02-13 |
| 2010-03-31 | $18.00K 10-Q · filed 2011-05-05 | -$421.00K derived: sum of 2 quarters · filed 2012-02-13 | -$973.00K derived: sum of 3 quarters · filed 2012-02-13 | -$65.00K derived: sum of 4 quarters · filed 2012-02-13 |
| 2009-12-31 | -$439.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-13 | -$991.00K derived: sum of 2 quarters · filed 2012-02-13 | -$83.00K derived: sum of 3 quarters · filed 2012-02-13 | $582.00K 10-K · filed 2012-02-13 |
| 2009-09-30 | -$552.00K 10-Q · filed 2010-11-04 | $356.00K derived: sum of 2 quarters · filed 2010-11-04 | $1.02M 10-Q · filed 2010-11-04 | |
| 2009-06-30 | $908.00K 10-Q · filed 2010-08-05 | $1.57M 10-Q · filed 2010-08-05 | ||
| 2008-12-31 | $719.00K 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |